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ABG, PH, PCO~2~, PaO~2~

:   arterial blood gas, potential hydrogen, partial pressure of carbon dioxide, and partial pressure of oxygen

AKI

:   acute kidney injury

ARDS

:   acute respiratory distress syndrome

BMI

:   body mass index

COVID‐19

:   coronavirus disease 2019

CXR

:   chest X‐ray

ECG

:   electrocardiography

ECHO

:   echocardiogram

ECMO

:   extracorporeal membrane oxygenation

ED

:   emergency department

NSAIDs

:   nonsteroidal anti‐inflammatory drugs

Key points {#jocs14925-sec-0070}
==========

**Question:** When should cardiac tamponade be suspected in COVID‐19 patients?

**Findings:** Patients may have cardiac tamponade and cardiac failure on presentation, or develop tamponade during their hospital course. It is important to rule out cardiac tamponade in patients with COVID‐19 experiencing cardiac arrest or worsening hemodynamic status. Up‐trending inflammatory markers, signifying systemic inflammatory response, may be associated with cardiac tamponade and concomitant ventricular failure.

**Question:** What can be done to prevent cardiac tamponade and ventricular failure in patients with COVID‐19?

**Findings:** While data is limited, systemic inflammation and hyper‐coagulopathy constitute the underlying pathophysiology of disease in COVID‐19 infection. Thus, therapeutic dose anti‐coagulation and anti‐inflammatory medications could possibly play a role in treatment of patients with COVID‐19. However, it is important to be cognizant of hemorrhagic sequalae and immunosuppressive side effects of these medications.

1. INTRODUCTION {#jocs14925-sec-0080}
===============

The World Health Organization declared the coronavirus disease 2019 (COVID‐19) outbreak as a pandemic on 11 March 2020.[^1^](#jocs14925-bib-0001){ref-type="ref"} With its rapid spread across the globe, physicians have encountered a broad spectrum of early and late complications---mostly resulting from the underlying inflammatory process---including acute respiratory distress syndrome, acute kidney injury, and secondary infection.[^2^](#jocs14925-bib-0002){ref-type="ref"}

Mortality among hospitalized patients with COVID‐19 has been reported to be as high as 17%, with the figure being 20.5% in patients undergoing elective surgeries.[^3^](#jocs14925-bib-0003){ref-type="ref"}, [^4^](#jocs14925-bib-0004){ref-type="ref"}

There is paucity of data regarding the cardiovascular effects of COVID‐19. Arrhythmias, myocarditis, hypercoagulability, congestive heart failure, and, surprisingly, two cases of cardiac tamponade physiology, both resulting from hemorrhagic pericardial effusion, have been reported.[^5^](#jocs14925-bib-0005){ref-type="ref"}, [^6^](#jocs14925-bib-0006){ref-type="ref"}, [^7^](#jocs14925-bib-0007){ref-type="ref"}, [^8^](#jocs14925-bib-0008){ref-type="ref"} We further report three cases of COVID‐19 complicated by cardiac tamponade requiring emergent surgical intervention.

2. CASE SERIES {#jocs14925-sec-0090}
==============

Case 1A 48‐year‐old Hispanic male with a past medical history of type 2 diabetes mellitus, morbid obesity (body mass index \[BMI\]: 39.5 kg/m^2^), with normal cardiac function and a known chronic small pericardial effusion of unknown etiology (not amenable to pericardiocentesis), presented with complaints of dyspnea and fatigue for 1 month, and acute deterioration for the past 24 hours. Nasopharyngeal swab was positive for COVID‐19, serum troponins were within normal range, and arterial blood gas (ABG) analysis showed a pH of 7.26, partial pressure of carbon dioxide (pCO~2~) of 83mm Hg, and partial pressure of oxygen (pO2) of 187mm Hg. Chest x‐ray demonstrated clear lung fields and a large cardiac silhouette. Echocardiogram (ECHO) showed a moderate‐to‐large pericardial effusion with tamponade physiology (Figure [1](#jocs14925-fig-0001){ref-type="fig"}).

He underwent emergent percutaneous drainage of 1500 mL of clear pericardial fluid which was sent for cytology (Table [1](#jocs14925-tbl-0001){ref-type="table"}) and was started on therapeutic anticoagulation. On postoperative day (POD) 8, the patient developed acute cardiovascular decompensation. An ECHO showed a large pericardial fluid collection with signs of obstructive shock (Figure [2](#jocs14925-fig-0002){ref-type="fig"}). He underwent another pericardial drainage with 900 mL of sanguineous fluid drained (no associated bacterial organisms on fluid culture), and was switched to prophylactic dose anticoagulation. Postoperative course was unremarkable, and patient was discharged 10 days after the second procedure in stable condition with drop in his inflammatory markers after Pericardiocentesis (Table [2](#jocs14925-tbl-0002){ref-type="table"}).

###### 

Pt 1 pericardial fluid cytology after first drainage

  Component               Data
  ----------------------- -------------------
  Amylase fluid           46
  Appearance, body F      Clear
  Baso fluid              0
  Cells counted body      100
  Eosinophils fluid       0
  Fluid type              Pericardial fluid
  Fluid type              Pericardial
  Fluid type              Pericardial
  Fluid type              Pericardial fluid
  Fluid type              Pericardial fluid
  Glucose, fluid          108
  Lymphs fluid            50
  Mesothelial fluid       11
  Monocyte fluid          6
  Nucleated cells fluid   198
  PH, pleural fluid       8.9
  Protein, fluid          5.0
  Red blood cell cou.     555
  Macrophage body         11
  Color fluid             Yellow
  Comment                 No established
  Neutrophils %, fluid    22
  Fluid lining cells      0
  Unidentified cells      0
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![A, Top left, subcostal view: There is a large circumferential pericardial effusion. B, Top right, continuous wave Doppler through the mitral valve in the four chamber apical view: This image shows significant (\>30%) respiratory variation in mitral inflow velocity. C, Bottom, subcostal view: There is a large circumferential pericardial effusion with visible partial collapse of the right ventricle and right atrium](JOCS-9999-na-g001){#jocs14925-fig-0001}

![Subcostal view: There is a large circumferential pericardial effusion](JOCS-9999-na-g002){#jocs14925-fig-0002}

![A, Top left, continuous wave Doppler through the mitral valve in the two chamber apical view: This image shows significant (\>30%) respiratory variation in mitral inflow velocity. B, Top right, apical four chamber view: There is a moderate size effusion adjacent to the right atrium with partial right atrial collapse. C, Bottom, subcostal view: The inferior vena cava is plethoric measuring 2.9 cm](JOCS-9999-na-g003){#jocs14925-fig-0003}

###### 

Pt 1 inflammatory markers during admission

                            04/15    04/16   04/17   04/18    04/19   04/20   04/21   04/22   04/23   04/24   04/25   04/26   04/27   04/28    04/29   04/30   05/01
  ------------------------- -------- ------- ------- -------- ------- ------- ------- ------- ------- ------- ------- ------- ------- -------- ------- ------- -------
  24 h                      0001     0001    0001    0001     0001    0001    0001    0001    0001    0001    0001    0001    0001    0001     0001    0001    0001
  Biomarkers                                                                                                                                                   
  D‐dimer quantitative      404              1.597   935      502             277             1.039           691     567             592      653     962     
  C‐reactive protein        19.74                    151.86           37.86                   35.20           32.97   15.06           31.25    15.03   10.84   
  Erythrocyte sedimentati                    35      57               49                      3               3                                7               
  Lactate dehydrogenase     317              372     330      319     297                     1.585           350     328                      267             
  AST                       62       59      46:     38       42      40                      1.592           1.290   374     133     83       68      69      69
  ALT                       229      184     104     65       60      62                      1.964           3.581   2.563   1.602   1.090    834     626     427
  Ferritin                  22               61E              105     80      54              1.307           620     228                      55              
  Procalcitonin             \<0.05                                                            0.76            0.20                    \<0.05                   
  Troponini                 \<0.1    \<0.1                                                    5.0     3.3     0.9     0.6                                      
  Creatine kinase total                      84      82                                       134                                                              
  Triglycerides                              84                                               72                                               78:             
  White blood cell count    10.2     9.6     9.0     14.2     11.7    9.5     9.3     11.2    14.4            11.2    10.5    17.0    15.1     16.4    16.2    9.7
  Neutrophils absolute      8.6      8.1     8.3                      9.0             9.7     29.5                            15.7             15.3            8.4
  Lymphocytes absolute      0.6      0.4     0.2                      0.2             0.6     0.5                             0.3              0.2             0.5
  Lymphocytes %             6        4       2                        2               5       2                               2                2               5
  Platelet count            139      108     101     107      81      104     98      112     184             192+    186     226     218      242     245     191
  Interleukin 6                              \<5                                                                                                               

Abbreviations: ALT, alanine aminotransferase; AST, aspartate transaminase.
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###### 

Pt 2 Inflammatory markers during admission

                           03/28   03/29   03/30
  ------------------------ ------- ------- -------
  24 h                     0001    0001    0001
  Biomarkers                               
  D‐dimer quantitative             \<202   
  C‐reactive protein               24.90   
  Lactate dehygenase               240     
  AST                      26      55      24
  ALT                      26      65      12
  Ferritin                         1.008   
  Procalcitonin                    0.08    
  Troponin I               1.2     0.5     
  Creatine kinase total            110     
  White blood cell count   5.5     4.5     
  Neutrophils absolute     4.5     3.6     
  Lymphocyte absolute      0.5     0.5     
  Lymphocyte %             9       12      
  Platelet count           95      82      

Abbreviations: ALT, alanine aminotransferase; AST, aspartate transaminase.
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###### 

Pt 3 inflammatory markers during admission

                                      03/25    03/26   03/27    03/28    03/29   03/30    03/31    04/01     04/02
  ----------------------------------- -------- ------- -------- -------- ------- -------- -------- --------- ---------
  24 h                                0001     0001    0001     0001     0001    0001     0001     0001      0001
  Biomarkers                                                                                                 
  D‐dimer, quantitative                                15.212   11.119           43.874                      
  C‐reactive protein                                   205.23   324.44           363.53   230.99             
  Erythrocyte sedimentati                              66       62               65                          
  Lactate dehydrogenase               Specim           2.445    2.303            1.997    1.941              
  AST                                                  Speci    143:             66       262                \>6.600
  ALT                                                  90       77               55       133                3.306
  Ferrtin                                              12.310   6.880            4.578                       
  Procalcitonin                                0.94                                                          
  Troponin                            0.4              0.3                                0.4                
  Creative kinase total               3.744            3.158    6.547    6.875   4.417    1.218              1.411
  Triglycerides                                                                           479                
  White blood count                   10.7     12.3    14.1     15.6     22.0    27.6     27.9     28.2      31.4
  Lymphocyte absolute cal             1.7      1.6     0.8      0.5      0.9     0.7                         
  Lymphocytes %                       13       12      6        3        4       3                           
  Platelet count                      255      236     231      228      200     141      92       60        51
  Interferon gama                                               \<5              \<5               \<5+      
  Interleukin 10                                                44               39                128       
  Interleukin 12                                                \<5              \<5               \<5+      
  Interleukin 13                                                \<5              \<5               \<5+      
  Interleukin‐1 beta                                            \<5              \<5               \<5+      
  Interleukin 2 receptor (CD25) sol                             524              See no            1.578+    
  Interleukin 2                                                 \<5              \<5               \<5+      
  Interleukin 4                                                 \<5              \<5               \<5+      
  Interleukin 5                                                 \<5              \<5               \<5+      
  Interleukin 6                                                 130              See no   See no   See n +   
  Interleukin 8                                                 \<5              \<5               35        
  Tumor necrosis factor‐alpha                                   \<5:             \<5               \<5−      

Abbreviations: ALT, alanine aminotransferase; AST, aspartate transaminase.
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Case 2A 56‐year‐old Hispanic overweight (BMI of 27.1 kg/m^2^) male with no significant medical history presented with a one‐week history of cough, chest pain, fever and chills. Laboratory investigations showed a serum troponin‐I level of 1.2 ng/dL and nasopharyngeal swab confirmed COVID‐19 infection. Over the next few hours, the patient developed progressive hypotension. ECHO showed a large pericardial effusion with tamponade physiology (no images recorded in system, as it was an emergent bedside ECHO), and a left ventricular ejection fraction of 20%. He underwent emergent drainage of 400 mL of serous pericardial fluid. On POD 0, the patient experienced cardio‐pulmonary arrest and expired. It\'s presumed that that cause of death was cardiogenic shock due to severe ventricular dysfunction resulting from COVID‐19 inflammatory storm or post‐drainage pericardial decompression syndrome. 9) Inflammatory markers can be seen in (Table [3](#jocs14925-tbl-0003){ref-type="table"}).

Case 3A 55‐year‐old African American male with a past medical history of hypertension and obesity (BMI of 30.5 kg/m^2^) presented with 2 weeks of dyspnea, productive cough, myalgias, fatigue, fever, and chills. ABG showed a pH of 7.46, pCO~2~ of 32mm Hg, and pO2 of 67mm Hg on 15 L of oxygen. Serum troponin‐I was within normal range, serum creatinine was 2.3 mg/d, and nasopharyngeal swab was positive for COVID‐19. CXR showed bilateral lung opacities and a mildly enlarged cardiac silhouette. He was started on prophylactic dose anti‐coagulation, intubated on hospital day 2 for progressive hypoxia, subsequently on hospital day 5, required Veno‐venous extra corporeal membrane oxygenation (ECMO) and was transitioned to prophylactic dose anti‐coagulation. Laboratory investigations during hospitalization are seen in (Table [4](#jocs14925-tbl-0004){ref-type="table"}). On hospital day 7, the patient developed pulseless electrical activity cardiac arrest. A bedside echocardiogram revealed a large pericardial effusion with tamponade physiology, and 800 mL of sanguineous fluid was drained percutaneously, with return of spontaneous circulation. On hospital day 8, due to increasing vasopressor and inotropic requirements, a repeat echocardiogram was performed which demonstrated biventricular failure, likely from post‐drainage pericardial decompression syndrome (Figure [3](#jocs14925-fig-0003){ref-type="fig"}). Further aggressive management was deemed futile, and all interventions were withdrawn per family\'s wishes; the patient underwent ECMO decannulation and was pronounced dead.

3. DISCUSSION {#jocs14925-sec-0100}
=============

COVID‐19 was confirmed in a cluster of patients by the Chinese health authorities on 7 January 2020. The first case in the United States was reported on 20 January 2020[^1^](#jocs14925-bib-0001){ref-type="ref"} With its continued spread globally, a range of complications affecting almost every organ system have been reported.

Cardiac tamponade is most commonly idiopathic, with a smaller subset of cases resulting from infectious causes. It can be due to collection of transudate, exudate or blood in the pericardium.[^9^](#jocs14925-bib-0009){ref-type="ref"}, [^10^](#jocs14925-bib-0010){ref-type="ref"} Viral pericarditis is usually characterized by a gradual accumulation of transudate. Interestingly, in COVID‐19 patients with cardiac tamponade, they can develop sanguineous, exudative or transudative pericardial fluid, as evidenced in our patients.[^6^](#jocs14925-bib-0006){ref-type="ref"}, [^7^](#jocs14925-bib-0007){ref-type="ref"}

The pathophysiology of COVID‐19 cardiac tamponade is possibly a result of the marked systemic inflammatory response to the virus, leading to myocarditis and pericarditis. Pericardial drainage can be followed by severe pericardial decompression syndrome, leading to paradoxical hemodynamic instability and/or pulmonary edema following an otherwise noncomplicated pericardial drainage.[^11^](#jocs14925-bib-0011){ref-type="ref"} Myocardial ischemia, can also be explained by the hyper‐coagulability (resulting from endothelial damage and the inflammatory response) in these patients.[^12^](#jocs14925-bib-0012){ref-type="ref"}, [^13^](#jocs14925-bib-0013){ref-type="ref"} Thus, prophylactic use of corticosteroids and therapeutic anti‐coagulation have been proposed in patients with COVID‐19.[^14^](#jocs14925-bib-0014){ref-type="ref"}

Cardiac tamponade should be suspected in COVID‐19 patients with progressive hemodynamic compromise. An echocardiogram showing late diastolic collapse of the right atrium and early diastolic collapse of the right ventricle (occurring when the intra‐pericardial pressure exceeds intracavitary pressure) is diagnostic.

After pericardial fluid drainage management is largely supportive, and recurrent cardiac tamponade is possible. While the use of therapeutic anticoagulation has been shown to improve prognosis in severe patients with COVID‐19[^14^](#jocs14925-bib-0014){ref-type="ref"} the development of sanguineous cardiac tamponade (as seen in Case [1](#jocs14925-mthst-0001){ref-type="statement"}) may point towards increased risks of therapeutic anticoagulation after initial drainage. However, given the documented benefits of therapeutic anticoagulation in patients with COVID‐19, particularly in patients with elevated D‐dimers, it might be judicious to resume anti‐coagulation 12 hours postoperatively, with a high index of suspicion for rebleeding in case of progressive worsening of hemodynamic status.[^12^](#jocs14925-bib-0012){ref-type="ref"}, [^15^](#jocs14925-bib-0015){ref-type="ref"}) The role of NSAIDs in this subpopulation is yet to be determined.[^16^](#jocs14925-bib-0016){ref-type="ref"}, [^17^](#jocs14925-bib-0017){ref-type="ref"} High suspicion for recurrence of cardiac tamponade is warranted as risk of recurrence is as high as 20%.[^18^](#jocs14925-bib-0018){ref-type="ref"}

While current data on cardiac tamponade, with possible concomitant biventricular failure, in patients with COVID‐19 are limited, we hypothesize that short‐term prognosis in this subpopulation is primarily dependent upon ventricular function at the time of development of tamponade, and also by development of post‐drainage pericardial decompression syndrome. In our case series, the two patients with cardiac tamponade with concomitant biventricular failure (Cases 2 and 3) experienced rapid deterioration leading to death, while the patient with preserved ventricular function (Case [1](#jocs14925-mthst-0001){ref-type="statement"}) survived. However, the observed ventricular dysfunction---possibly stress cardiomyopathy or cytokine‐related myocardial dysfunction---may just be a manifestation of the overall severity of inflammatory response and the associated fulminant cytokine release (Tables [1](#jocs14925-tbl-0001){ref-type="table"}, [2](#jocs14925-tbl-0002){ref-type="table"}, [3](#jocs14925-tbl-0003){ref-type="table"}).[^19^](#jocs14925-bib-0019){ref-type="ref"} Further, the long‐term prognosis, sequelae and predictors of survival in patients with COVID‐19 developing transient myocarditis or cardiac tamponade remain yet to be observed.[^20^](#jocs14925-bib-0020){ref-type="ref"}, [^21^](#jocs14925-bib-0021){ref-type="ref"}

Importantly, surgical intervention and drainage of pericardial fluid in patients with COVID‐19, while allowing for rapid relief from tamponade physiology, is associated with intra‐ and postoperative risks.

As mentioned in our study, all three patients who developed cardiac tamponade, a severely morbid complication, were of either African American, or Hispanic race. COVID‐19 has been more deadly for African American and Hispanic people as seen in studies published in the US and the UK.[^22^](#jocs14925-bib-0022){ref-type="ref"}

4. LIMITATIONS {#jocs14925-sec-0110}
==============

Our study is limited by the small sample size, and inability to test pericardial fluid for COVID‐19 antibodies and fluid composition.

5. CONCLUSION {#jocs14925-sec-0120}
=============

Cardiac tamponade is a rare complication of COVID‐19 infection. Physicians must be cognizant of this possibility in patients with cardiovascular decompensation. Ultrasonography can aid in rapid diagnosis, and drainage of pericardial fluid and can result in clinical improvement. Short‐term prognosis appears to depend upon ventricular function. Role of corticosteroids, NSAIDs, and immune modulators remains unclear in this subgroup of COVID‐19 patients, but may have a role in preventing the development of ventricular failure caused by the marked inflammatory response and stress cardiomyopathy.
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